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Drug shortages are a complex and global phenomenon. When a drug cannot be delivered at the 
moment of patient demand, every stakeholder in the health care system is affected. The aim of 
this study was to investigate the characteristics, clinical impact, financial impact and 
management of drug shortages in European hospital pharmacies and identify opportunities for 
prevention and mitigation of drug shortages in Europe. An online survey was designed based 
on a review of the literature and interviews and was sent to subscribers of Hospital Pharmacy 
Europe between June and September 2013. Forty-five percent of respondents (n=161) indicated 
that life sustaining or life preserving drugs such as oncology drugs were affected by drug 
shortages. More than 30% of respondents indicated that drug shortages in Europe were always 
or often associated with increased costs for hospitals, increased personnel costs and more 
expensive alternative drugs (n=161). On the question when information about a drug shortage 
was obtained, 42% of respondents answered that information from the pharmaceutical company 
was obtained at the time of no delivery, 50% indicated that information from the wholesaler 
was obtained at the time of no delivery, while 40% of respondents indicated that information 
was never or rarely received from the government (n=161).   Fifty seven percent of respondents 
strongly agreed that an obligation to the producer to notify further shortages could help to solve 
the problem (n=161). These results showed that pharmaceutical companies and wholesalers are 
already involved in the management of drug shortages, while a role is still reserved for the 
government. Mandatory notification in advance and centralized information can help to reduce 
workload for hospital pharmacists, will allow early anticipation of drug shortages and will 





Introduction  1 
A drug shortage can be defined as a shortcoming in the supply of a medicinal product that 2 
affects the patient’s ability to access the required treatment in due time. The origins of drug 3 
shortages are complex and diverse and the problem can be situated at both the supply and 4 
demand side [1,2]. Drug shortages affect every stakeholder of the health care system and 5 
collaborative efforts are required to manage and mitigate shortages [3]. Drug shortages are 6 
likely to affect workload and clinical decision-making and a clinical and financial impact needs 7 
to be anticipated [4,5]. 8 
An inquiry of United States (US) health care workers showed that in up to 99% of surveyed 9 
hospitals, drug shortages were experienced in the months preceding that study [6–8]. 10 
Pharmacists are often the first health care professionals who will be faced with the shortage. 11 
They will start seeking solutions for the problem and initiate negotiations with manufacturers 12 
and wholesalers. Furthermore, physicians and nurses need to be informed to consider future 13 
treatment options [3]. The drug in short supply can often be substituted by alternative drugs but 14 
in some cases such as for chemotherapy or antibiotics, alternatives are of little help [9]. 15 
Alternatives potentially have lower efficacy or suboptimal safety profiles and deliberation about 16 
alternative agents with physicians, nurses and other health care workers is required [10].  17 
Delayed treatment or switches to alternative therapies can result in disease progression, 18 
increased risk for adverse effects or medication errors and reduced compliance [4,5]. Although 19 
all disease domains are affected by shortages, many of the drugs involved in US drug shortages 20 
are considered to be high alert medications such as heparin and propofol [3,6,11]. Their shortage 21 
does not only impact patient safety but also hospital performance in cases where treatment or 22 
surgery needs to be postponed, cancelled or even transferred to other hospitals where the 23 
necessary treatments are still available [6,8]. Surveys conducted in the US revealed that 24 
pharmacists often learn about the shortage at the moment they fail to receive an ordered product 25 
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from the wholesaler or manufacturer (i.e. at the time of no delivery) [8]. Besides lack of 26 
advanced notification of the drug shortage, health care workers mentioned that the information 27 
they received about shortages was often inadequate [12]. Labor costs associated with managing 28 
drug shortages are estimated at $216 million annually in the U.S. [12]. The financial impact of 29 
drug shortages where generic equivalent alternatives are available exceeds $78 million with the 30 
highest cost impacts coming from infectious diseases, surgery, oncology and cardiovascular 31 
diseases [1]. The purchase of overall equivalent or alternative therapeutic substitutes is 32 
estimated to cost US hospitals about 215$ million annually [10].  33 
Despite numerous articles appearing in the pharmaceutical trade magazines, facts and figures 34 
about drug shortages in Europe are rarely reported in the scientific literature [11–16].   Studies 35 
about the effect of drug shortages in European hospitals are limited. In 2012, the European 36 
Association of Hospital Pharmacists (EAHP) launched a questionnaire concerning drug 37 
shortages in European hospitals [17]. The questionnaire results revealed that 99% of hospital 38 
pharmacists experienced shortages in the past year [19]. According to the respondents, shortages 39 
occurred weekly and sometimes daily and the problem has emerged over the past years. On the 40 
question of whether patient care is affected by shortages, opinions are diverse with 50% of 41 
respondents saying it is affected while another 46% of respondents indicated that the hospital 42 
is able to manage the problem without the patient being affected [19]. Nevertheless, it cannot 43 
be neglected that drug shortages are also affecting European hospitals and that this puts the 44 
patients at risk. The hurdles in the management of drug shortages need to be identified and 45 
conquered to allow optimal patient care. Therefore the aim of this study was to further 46 
investigate the characteristics, impact, causes and management of drug shortages in European 47 
hospital pharmacies and identify opportunities for prevention and mitigation of drug shortages 48 




Because of the nature of the survey, it was not required to seek approval from a research 51 
ethics committee. Data were analyzed anonymously. 52 
 53 
A survey about drug shortages in European hospital pharmacies was developed based on a 54 
review of the literature [1,3,6,7,17–20] and five interviews with Belgian pharmacists. The 55 
online survey was setup in SurveyMonkey (2013) and tested by three authors of the manuscript, 56 
one student involved in the project, three affiliates of the project sponsor and the members of 57 
the editorial board of Hospital Pharmacy Europe (HPE) to collect comments about the length 58 
of the survey and clarity of the questions. The final survey included 29 questions. The survey 59 
enquired about the characteristics  of  the hospitals where respondents work, whether particular 60 
drug classes are more affected by shortages than others, which disease domains are affected by 61 
drug shortages and how shortages in particular disease domains can be characterized. 62 
Additionally, the clinical and financial impact, reported causes, measures to handle shortages, 63 
channels to obtain information about the drug shortage and possible solutions were questioned. 64 
The respondents were asked to estimate time spent per week (number of hours) on the 65 
management of drug shortages.  A copy of the survey can be obtained upon request. 66 
The survey was launched in the May-June issue of HPE which was distributed on the first of 67 
June 2013 to 12,000 subscribers. The first response was received on 7 June 2013. From then 68 
on, a link to the survey was announced in the weekly online bulletin of HPE, sent to 7,000 69 
subscribers. The survey was closed on 15 September 2013.  70 
The answers of respondents employed in European countries who completed the first four 71 
questions of the survey (country of origin, type of hospital (acute/university/psychiatric),  size 72 
of hospital and the question “do you have the impression that particular drug types suffer more 73 
from shortages than others?”) were considered for further analysis.  74 
Only descriptive statistics were performed. Characteristics of drug shortages were compared 75 
between different geographical regions i.e. Northern Europe, Eastern Europe, Southern Europe 76 
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and Western Europe, based on the classification of European countries by the United Nations 77 
Statistic Division [21]. When at least ten respondents of the same country fulfilled the 78 
requirements for inclusion as described above, the country was additionally included in the 79 
analysis as such. Clinical and financial impact, causes for drug shortages and measures to 80 
handle drug shortages and possible solutions were analyzed for overall respondents.  Relative 81 
numbers were presented as percentages and the considered sample size (n) was included in the 82 
result. The respondents were also asked to estimate the time spent on different items related to 83 
management of shortages. The number of hours per week spent on the management of drug 84 
shortages was estimated by the median number of hours obtained over all answers. 85 
 86 
Results  87 
Characteristics of respondents 88 
Two hundred and eighty respondents participated in the survey. Of these, 161 respondents were 89 
retained for further analysis based on relevance of their country of origin for this study (e.g. 90 
European country) and completion of the first five questions of the survey. Twenty nine percent 91 
of European respondents were working in a hospital in Western Europe, 34% in Northern 92 
Europe, 21% in Southern Europe and 16% in Eastern Europe (n=161). An analysis was also 93 
performed for Belgium (n=11), the Netherlands (n=16) and United Kingdom (UK) (n=44). The 94 
majority of the European respondents reported  working in an acute hospital (56%), while 37% 95 
were working in a university hospital and 7% were based in a psychiatric hospital (n=161).  96 
Characteristics of drug shortages 97 
Seventy nine percent of respondents indicated that particular drug classes were more affected 98 
by shortages than others (n=161). In Europe, the largest share of respondents indicated life 99 
preserving and life sustaining drugs were most affected by drug shortages (figure 1). This was 100 
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also reflected in the regions and countries, except for Northern Europe and the UK (figure 1). 101 
Here an important number of respondents indicated that drugs for management of long-term or 102 
chronic health issues suffered from shortages (figure 1). Next it was investigated in which 103 
disease domain drugs were affected by shortages. Anti-infective drugs and cancer drugs were 104 
indicated by the majority of respondents as being affected by drugs shortages in Europe (figure 105 
2-3). The drug shortages were specified as generic, cheap drugs for injectable administration 106 
(figure 2-3). Similar results were obtained for most regions and countries even though a large 107 
part of the UK respondents indicated that cancer drugs were not affected by shortages (figure 108 
3). Drugs for cardiovascular diseases were affected by shortages according to a large share of 109 
respondents from Northern Europe (33% indicated “yes”, 27% indicated “no” and 40% 110 
provided no answer, n=55), UK (34% indicated “yes”, 25% indicated “no” and 41% provided 111 
no answer, n=44) and the Netherlands (50% indicated “yes”, 44% indicated “no” and 6% 112 
provided no answer, n=16). Drugs for the central nervous system were reported to suffer from 113 
shortages by a large share of respondents from Northern Europe (51% indicated “yes”, 27% 114 
indicated “no” and 22% provided no answer, n=55), UK (55% indicated “yes”, 23% indicated 115 
“no” and 23% provided no answer, n=44) and Eastern Europe (35% indicated “yes”, 27% 116 
indicated “no” and 38% provided no answer, n=26). For immunological products and vaccines, 117 
shortages were indicated by a major share of respondents from Southern Europe (35% indicated 118 
“yes”, 29% indicated “no” and 35% provided no answer, n=34), Western Europe (33% 119 
indicated “yes”, 26% indicated “no” and 41% provided no answer, n=46) and the Netherlands 120 
(44% indicated “yes”, 31% indicated “no” and 25% provided no answer, n=16).  121 
Figure 1 Drug types affected by drug shortages according to the respondents. Respondents 122 
who indicated that particular types of medicines suffered more from shortages than others were 123 
considered. The relative number of respondents per answer was shown for Europe (n=128), 124 
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Northern Europe (n=8), Eastern Europe (n=20), Southern Europe (n=30), Western Europe 125 
(n=16), the UK (n=29), Belgium (n=9) and the Netherlands (n=15). 126 
Figure 2 Characteristics of drug shortages for anti-infective drugs per region and country. 127 
A. Answers to the question “Are anti-infective drugs affected by drug shortages?”. The relative 128 
number of respondents per answer was shown for Europe (n=161), Northern Europe (n=55), 129 
Eastern Europe (n=26), Southern Europe (n=34), Western Europe (n=46), the UK (n=44), 130 
Belgium (n=11) and the Netherlands (n=16). B. Answers to the question “If yes, are these 131 
affected drugs mostly generic or originator drugs?”. C. Answers to the question “Are these 132 
affected drugs mostly cheap or expensive?”. D. Answers to the question “What is the most 133 
affected form?”. For figure B-D, respondents who indicated the disease domain is affected were 134 
considered. The relative number of respondents was shown for Europe (n=69), Northern Europe 135 
(n=24), Eastern Europe (n=10), Southern Europe (n=13), Western Europe (n=21), the UK 136 
(n=17), the Netherlands (n=9).  137 
Figure 3 Characteristics of drug shortages for cancer drugs per region and country. A. 138 
Answers to the question “Are cancer drugs affected by drug shortages?”. The relative number 139 
of respondents per answer was shown for Europe (n=161), Northern Europe (n=55), Eastern 140 
Europe (n=26), Southern Europe (n=34), Western Europe (n=46), the UK (n=44), Belgium 141 
(n=11) and the Netherlands (n=16). B. Answers to the question “If yes, are these affected drugs 142 
mostly generic or originator drugs?”. C. Answers to the question “Are these affected drugs 143 
mostly cheap or expensive?”. D. Answers to the question “What is the most affected form?”. 144 
For figure B-D, only respondents who indicated the disease domain were affected by shortages 145 
were considered. The relative number of respondents was shown for Europe (n=83), Northern 146 
Europe (n=18), Eastern Europe (n=17), Southern Europe (n=20), Western Europe (n=27), 147 
Belgium (n=4), the Netherlands (n=13). 148 
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Impact of drug shortages 149 
According to figure 4, a majority of respondents indicated that patients were rarely or never 150 
referred to another hospital due to drug shortages. Further, most respondents indicated drug 151 
shortages rarely or never led to a switch to a lower dose (figure 4). Substitution with equivalent 152 
drugs was indicated to occur always or often by a large share of respondents, while medication 153 
errors and substitution with inferior drugs occurred sometimes according to a major share of 154 
respondents (figure 4). The opinions with regard to rationing of the drug and delay of therapy 155 
were more diverse (figure 4). On the financial level, increased hospital costs, increased 156 
pharmacy or personnel costs and the use of more expensive alternatives were indicated by a 157 
majority of respondents as consequences of drug shortages that occur always or often (figure 158 
5). Cost for patients was indicated by a large share of respondents as being rarely or never 159 
affected by drug shortages (figure 5).  160 
Thirty seven percent of respondents indicated that the personnel stress was (very) severely 161 
affected by shortages while 22% indicated that this was moderately affected, 10% of 162 
respondents indicated this was not/little affected and 37% of respondents provided no answer 163 
(n=161).  164 
The total time spent on the management of shortages by hospital pharmacists was estimated to 165 
be 12.8 hours/week. Most time was spent on tracking shortages (2.2 hours/week). Identifying 166 
therapeutic alternatives, purchasing therapeutic alternatives, deliberating with physicians and 167 
changing stock each required 2.0 hours/week. The development of policies required 1.6 168 
hours/week while only one hour per week was spent on education of nursing staff. Of the 161 169 
respondents, 35% of respondents provided no answer on this question.  170 
Figure 4 Answers to the question “What clinical impact has a drug shortage already 171 
caused in your hospital?” The relative number of respondents per answer was shown (n=161). 172 
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The answer “always” and “often” as well as “never” and “rarely” were grouped for the sake of 173 
clarity.  174 
Figure 5 Answers to the question “Which financial consequence has a drug shortage 175 
already caused in your hospital?” The relative number of respondents per answer was shown 176 
(n=161). The answer “always” and “often” as well as “never” and “rarely” were grouped for 177 
the sake of clarity.  178 
Causes of drug shortages 179 
A majority of respondents believed that manufacturing problems were always or often the cause 180 
of drug shortages (figure 6). Too high prices, too many competitors, the economic crisis and 181 
high quality requirements from authorities were rarely or never the cause of drug shortages 182 
according to a large share of respondents (figure 6). For other possible causes, the answers were 183 
more diverse (figure 6). Tendering was estimated to play a role in drug shortages by the majority 184 
of respondents from Northern Europe (36% indicated “yes, 31% indicated “no” and 33% 185 
provided no answer, n=55), Eastern Europe (27% indicated “yes”, 19% indicated “no” and 54% 186 
provided no answer, n=26), the UK (36% indicated “yes”,  30% indicated “no” and 34% 187 
provided no answer, n=44) and the Netherlands (50% indicated “yes”, 44% indicated “no” and 188 
6% provided no answer, n=16). 189 
Figure 6 Answers to the question “What do you think are the causes for drug shortages 190 
over the last 12 months?” The relative number of respondents per answer was shown (n=161). 191 
The answer “always” and “often” as well as “never” and “rarely” are grouped for the sake of 192 
clarity.  193 
Measures against drug shortages  194 
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A large share of respondents indicated that information was rarely or never received from a 195 
professional association (28% indicated “rarely-never”, 19% indicated “sometimes”, 16% 196 
indicated “often or always” and 37% provided no answer, n=161), another hospital (28% 197 
indicated “rarely-never”, 22% indicated “sometimes”, 14% indicated “always or often” and 198 
37% provided no answer, n=161) or from the government (40% indicated “rarely-never”, 16% 199 
indicated “sometimes” , 7% indicated “always-often” and 37% provided no answer, n=161). 200 
When asking respondents when they received information about a drug shortage from a 201 
professional association, most respondents indicated that they only obtained information at the 202 
moment they were willing to deliver the drug and they were not able to fulfill this task due to 203 
unavailability of the drug (28% indicated “at the time of no delivery”, 20% indicated “in 204 
advance”, 16% indicated “never” and 37% provided no answer, n=161). Also other hospitals 205 
provided information at the moment hospital pharmacists faced a drug shortage (30% indicated 206 
“at the time of no delivery”, 16% indicated “in advance”, 18% indicated “never” and 37% 207 
provided no answer, n=161). Information was often, always or sometimes obtained from a 208 
pharmaceutical company (26% indicated “always-often”, 25% indicated “sometimes”, 12% 209 
indicated “rarely-never” and 37% provided no answer, n=161) and wholesalers (21% indicated 210 
“always-often”, 27% indicated “sometimes”, 16% indicated “rarely-never” and 37% provided 211 
no answer, n=161), respondents indicated that also in this case,  information was obtained at 212 
the time of no delivery for both pharmaceutical companies (42% indicated “at the time of no 213 
delivery”, 19% indicated “in advance”, 3% indicated “never” and 37% provided no answer, 214 
n=161) as well as for wholesalers (50% indicated “at the time of no delivery”, 10% indicated 215 
“in advance”, 4% indicated “never” and 37% provided no answer, n=161). Information 216 
provided by the government was never obtained according to a majority of respondents (40% 217 
indicated “rarely-never”, 16% indicated “sometimes”, 7% indicated “always-often” and 37% 218 
provided no answer). In order to obtain an equivalent product parallel import was always or 219 
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often used by 16% to obtain an equivalent product and by 20% of respondents to obtain an 220 
alternative product, while a similar number of respondents indicated they use parallel import 221 
sometimes, rarely or never and 37% of the respondents provided no answer (n=161).  222 
A majority of respondents (54%) indicated an effort to solve the shortage was sometimes made 223 
by the manufacturer. Five percent indicated that the manufacturer never made an effort and four 224 
percent indicated that an effort to solve the shortage was always made by the manufacturer. 225 
Thirty seven percent of respondents did not answer this question (n=161).  226 
An obligation to the producer to notify further shortages could help to solve the problem 227 
according to more than half of the respondents  (57% indicated “strongly agree”, 4% indicated 228 
“don’t know”, 2% indicated “(strongly) disagree” and 37% provided no answer, n=161) while 229 
52% of respondents (strongly) disagreed to reduce quality requirements (9% indicated “don’t 230 
know”, 2% indicated “(strongly) agree” and 37% provided no answer, n=161). 231 
 232 
Discussion  233 
Drug shortages are a complex and global problem [22]. While extensively studied in the US, 234 
drug shortages in European countries are yet little empirically investigated despite the fact that 235 
there are numerous reports that they frequently occur [11–15,23–25]. This study explores the 236 
phenomenon of drug shortages based on experiences of hospital pharmacists in a broad set of 237 
European countries. An inquiry into the characteristics of drug shortages showed that the 238 
typology of drug shortages differs between European regions and countries. Further, drug 239 
shortages in Europe were associated with a clinical and financial burden and additional 240 
workload for the hospital pharmacy. Perception of actions and measures already taken to 241 
manage shortages can reveal opportunities for further restriction of drug shortage impact on 242 
patients, healthcare workers and the hospital.  243 
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According to the results of this survey, drug shortages for life preserving and life sustaining 244 
drugs such as anti-infectives and cancer drugs are frequent in Europe. These findings are in 245 
accordance with a typology of US drug shortages presented by an IMS report [26]. Also other 246 
reports about drug shortages in US confirm shortages for anti-infectives such as antibiotics 247 
[3,6]. In a survey by the American Hospital Association (AHA), anesthetics and also drugs for 248 
emergency care are more often reported to be affected by drug shortages than anti-infectives 249 
and cancer drugs [7]. These shortages will affect health care workers as they can experience 250 
stress when providing surgery or emergency care, which can influence reporting of these 251 
shortages. In our study, drug shortages for anesthetics were only limitedly reported and the 252 
survey did not specifically question drug shortages in emergency care.  253 
Shortages in Europe mostly involved cheap generic and injectable drugs. It is often assumed in 254 
the literature that injectable drugs are most susceptible to manufacturing problems or quality 255 
issues due to the complexity of the production process, high quality requirements and small 256 
margin for errors [2,20]. The susceptibility to drug shortages of generic injectables is sometimes 257 
linked to a lack of market attractiveness for generics [27,28]. A high price pressure would 258 
discourage marketing of generics and reduces investments in facilities and quality control, 259 
increasing susceptibility to what is perceived as manufacturing or quality issues, while 260 
economic issues might be the root of the problem [27,28]. The potential role of price and 261 
reimbursement policies on market attractiveness and availability of drugs in US is discussed in 262 
the literature [27,28]. The European market is shaped by regulations and policies at European 263 
and national level. Each country applies its own regulations for the supply and market access 264 
of pharmaceuticals, all having possible influences on the availability of drugs [29]. In European 265 
countries and regions, the typology of drug shortages is indeed heterogeneous. Respondents 266 
from the UK, the Netherlands and Eastern Europe indicated tendering as a cause of drug 267 
shortages. Tendering puts a high pressure on drug prices, especially when the number of 268 
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competitors that participate in the tender is large. Furthermore, tendering can limit the number 269 
of suppliers, making drugs more susceptible to shortages when other suppliers need to start 270 
from zero to address a shortcoming in supply (e.g. capacity problem) [12,16,29,30]. According 271 
to the results of the survey, drug shortages in these tender markets were not limited to injectable 272 
drugs but also show up for the ‘less susceptible’ oral drugs such as drugs for cardiovascular 273 
diseases and the central nervous system. This strengthens the hypothesis that the cause of drug 274 
shortages goes beyond pure manufacturing problems related to technical issues or quality 275 
problems and can also involve economic factors. The European Directive 2004/18 from 31 276 
March 2004 requires hospitals to purchase all supplies and services through public procurement 277 
[31]. On 15 January 2014, the criterion of most economically and advantageous tender (MEAT) 278 
was introduced to emphasize the importance of quality/price ratio of the offer instead of just 279 
accepting the lowest price. The new directive was expected to enter into force end of March 280 
2014. In the Netherlands, the Royal Dutch Association for promotion of Pharmacy (KNMP) 281 
already developed an action plan to adjust the preferential policy (e.g. a tender-like system) and 282 
add a guarantee for sustainable supply to the conditions to win a tender [32].  283 
Also parallel trade is blamed as a cause of drug shortages in Europe. The European market is a 284 
single market, which enables the free trade of goods, including pharmaceuticals, across the 28 285 
Member States. After a patent holder has placed its products on the market, his intellectual 286 
property rights are exhausted and (cross border) trade with the product is allowed and can cause 287 
unforeseen export consequently leading to drug shortages [33].  Parallel trade has become 288 
important in the UK since the low value of the pound motivates wholesalers to buy products at 289 
a low price in the UK and sell them in high price countries such as Sweden and Germany 290 
[13,34]. Eastern Europe is even more characterized by the lowest prices among Europe, making 291 
countries in this jurisdiction an attractive market for export. In Poland, prices are on average 292 
30% lower than in Germany [35].  Drug shortages for schizophrenia in Slovakia, where the drug 293 
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price is set based on the second lowest price available in Europe, were also related to parallel 294 
trade [35-37].  Parallel trade is likely to particularly affect shortages of the patented medicines 295 
due to high prices of such medicines and bigger financial incentives for the wholesalers. In case 296 
of generics, large price disparities across the Member States can increase the role of parallel 297 
trade, particularly affecting countries with comparatively low prices of generic medicines [29]. 298 
Parallel trade was however poorly recognized by respondents in our study which can be 299 
explained by the fact that parallel trade affects the hospital drugs to a lesser extent than drugs 300 
distributed via community pharmacies. Hospital pharmacists presented manufacturing 301 
problems as the most important cause of drug shortages. 302 
Although it was already indicated by previous studies that pharmacists are not systematically 303 
informed about the cause behind a shortage [8,17], manufacturing problems can still play a role 304 
irrespective of economic root causes presented above. For example, immunological products 305 
involve a large amount of biologically active ingredients which are unique and cannot be 306 
included in tendering. For classes such as immunological products, it is likely that real 307 
manufacturing issues or quality problems are involved in shortages [2,20].  308 
Regardless of the cause, when a product cannot be delivered at the moment of patient demand, 309 
every stakeholder of the health care supply chain is affected. According to US studies, the 310 
purchase of alternative drugs causes additional costs for the hospital due to reimbursement 311 
restrictions [4,7]. Our study confirmed that the hospital itself is disadvantaged by drug shortages 312 
due to more expensive alternatives and additional hospital costs while patients remain free from 313 
financial burden. Patients will however not escape from a clinical impact. Substitution with 314 
alternative drugs can imply medication errors, adverse effects and disease progression. Drug 315 
shortages are related to clinical risks such as medication errors in this study as well as in other 316 
reports [7,8]. Other studies report a high number of “near miss errors”, including errors in 317 
dosing conversions and the preparation of wrong concentrations that never reach the patient 318 
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[4,8]. Near miss errors were not included in this questionnaire and also patient outcomes were 319 
not surveyed. In addition, the pharmacy personnel is not always aware of clinical incidents and 320 
can underestimate the impact of drug shortages.  321 
Pharmacists often succeed in obtaining an equivalent for the drug in shortage but this required 322 
a considerable amount of time. The workload associated with identification and purchase of 323 
alternative treatments might be reduced by increasing collaboration and sharing information 324 
between different hospitals, but the competitiveness between hospitals may make this unlikely. 325 
The median number of working hours to manage shortages estimated in this study is comparable 326 
to a survey carried out in the UK by the pharmacists’ organization Chemist+Druggist that 327 
previously showed that 95% of pharmacists spent between one and two hours per week on 328 
tracking out-of-stock drugs [14]. Another study conducted in US confirmed that pharmacists 329 
spent in total 9 hours per week to the management of drug shortages [3]. It was not always clear 330 
whether respondents considered the total number of working hours spent by their unit, or the 331 
number of hours per pharmacist. The workload related to drug shortages in general is 332 
underestimated because other health care workers such as physicians and nurses are also 333 
charged with the management of shortages [3]. Physicians are inevitably involved in 334 
deliberation about therapeutic alternatives while education of nursing staff was one of the 335 
actions to which the smallest amount of time was spent. According to other studies, nurses sense 336 
ignorance when they are not aware which alternative medications to consider and when they 337 
are unfamiliar with dosing and administration of alternative drugs in case of shortages [6,8]. 338 
Improving education of nursing staff might be one of the targets to limit the occurrence of 339 
medication errors.  340 
Personnel stress suggests a high level of frustration and sense of responsibility by hospital 341 
pharmacists. Other studies relate a high level of frustration to the lack of notification in advance 342 
of drug shortages [8]. Although respondents indicated information was provided by 343 
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pharmaceutical companies and wholesalers, information was not provided in advance. The 344 
government was limitedly involved in the management of a shortage. A mandatory early 345 
notification of drug shortages imposed by the government will allow health care workers to 346 
anticipate a drug shortage in an early stage. In this way, a financial burden on the hospital can 347 
be mitigated. Further, early notification will allow well-timed education of health care workers 348 
about the use of alternative drugs. As a result, clinical effects of drug shortages can be reduced.  349 
Further, the possible impact of cost-containment policies, such as tendering, on the availability 350 
of drugs needs to be considered and applied with respect to the sustainability of the market. 351 
Currently, insights into the causes of drug shortages are lacking and all players of the drug 352 
supply chain tent to blame each other and evade responsibility instead of taking action.  353 
This study suffers from several limitations. Firstly, as this study assumes drug shortages can be 354 
influenced by national policies, the regions considered in this study can be too broad to detect 355 
country-dependent effects. Secondly, some terms used in the questionnaire are not further 356 
defined to respondents and might be subjected to different interpretations. This is particularly 357 
important with regard to causes of drug shortages as the term manufacturing problems may 358 
cover problems with economic root causes such as tendering. Thirdly, the response rate for 359 
particular questions was relatively low. This can be due to the length of the questionnaire as 360 
well as to the retrospective nature of particular questions which makes it difficult to answer.  361 
 362 
Conclusion 363 
This study investigated the characteristics, impact, causes and management of drug shortages 364 
in European hospital pharmacies. A role for European and national policy measures related to 365 
the market access (e.g. tendering) and trade of pharmaceuticals (e.g. parallel trade) in the cause 366 
of drug shortages was suggested. Further, drug shortages in Europe are associated with a 367 
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financial burden on hospitals, workload for the hospital pharmacy and clinical risks for patients. 368 
Based on our results, opportunities for better prevention and mitigation of drugs shortages in 369 
Europe could be identified. While pharmaceutical companies and wholesalers are already 370 
involved in providing information and solutions, a role is still left for the government. 371 
Mandatory early notification of drug shortages, imposed by the government can help to 372 
anticipate the clinical impact of shortages while centralization of information is likely to reduce 373 
the workload for hospital pharmacists.  374 
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